**Logic Model: Angiotensin Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy**

**Intermediate Outcomes:**

Slowing the progression of kidney disease, lowering blood pressure, reducing proteinuria (albuminuria) (e.g., protein in urine).

**Final Outcomes:**

Reduction in kidney failure incidence, cardiovascular events, and death in patients with CKD.

**Clinical Action:**

* Patient identified as meeting criteria.
* Patient receives timely, high quality, evidence-based care.